Overall, these studies identify PYROXD2 as a potential regulator of muscle homeostasis in patients with CHF by controlling metabolic homeostasis, mitochondrial function, and fiber atrophy via a redox‐dependent pathway. Here, PYROXD2 is linked to congestive heart failure.